|
Greenwood, James C.
U.S House of Representatives (R-Penn) (1993-2004); "he authored numerous bills signed into law including legislation
to promote pediatric labeling for pharmaceuticals, reform medical device review and approval, and expand research and establish innovative programs to address traumatic brain injury. His legislation to reform medical liability insurance passed the House several times but stalled in the Senate. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over all issues in the full Committee's vast jurisdiction. He held hearings on topics ranging from bioterrorism to corporate governance to the safety of nuclear power plants." (1)
In 2004 "a high-profile congressional hearing into the safety of antidepressant medicines was abruptly canceled... by a House panel whose chairman [Greenwood] is reported to be considering an offer to become president of the Biotechnology Industry Organization, whose members include most of the pharmaceutical companies that were to send representatives to testify at the hearing... The hearing had been called to investigate pharmaceutical companies that have kept negative data about their antidepressant medications secret... Executives from seven pharmaceutical companies were to testify at the hearing... Bristol-Myers Squibb Co., GlaxoSmithKline, Eli Lilly and Co., Pfizer Inc. and Wyeth are all members of the Biotechnology Industry..." (2)
Assumed the post of president of the Biotechnology Industry Organization (BIO) in January 2005. (3)
Endnotes:
(1) Biotechnology Industry Organization profile at http://www.bio.org/aboutbio/vp/president.asp , accessed Jan 18, 2005
(2) Vedantam, Shankar. Hearing on Antidepressants Canceled. Washington Post, July 21, 2004; Page A04. At http://www.washingtonpost.com/ac2/wp-dyn/A106-2004Jul20
(3) Biotechnology Industry Organization news release, Jan 5, 2005, at http://www.bio.org/news/newsitem.asp?id=2005_0105_01
|
